Text: Editorial Staff
The IPN Biotherapeutics Development and Research Unit to Participate in BIO 2025, June 16–19
The Biotherapeutics Development and Research Unit (UDIBI) of the Instituto Politécnico Nacional (IPN) will take part in the 2025 BIO International Convention, scheduled for June 16–19 at the Boston Convention and Exhibition Center in Massachusetts.
UDIBI-IPN will be showcased at booth 1079 within the Mexico Pavilion, reaffirming its role as a national leader in biotherapeutics innovation and a proud representative of IPN’s commitment to scientific excellence on the global stage.
The Unit is dedicated to biotechnology research, training, and knowledge generation, in alignment with IPN’s mission to advance Mexico’s scientific and technological development.
UDIBI operates a nationally certified laboratory endorsed by the Federal Commission for the Protection against Sanitary Risk (Cofepris), focused on the research, development, and production of biotherapeutic products. Its multidisciplinary team of more than 70 experts specializes in molecular biology, immunology, pharmacology, and preclinical evaluation.
UDIBI’s participation in BIO 2025 positions the Unit for strategic visibility, enabling direct engagement with potential commercial partners, regulatory bodies, investors, and international media.
The Mexico Pavilion will also feature representatives from the Consulate General of Mexico in Boston; CARNOT Laboratories; AMIIF; Apotex Inc.; Liomont Laboratories; PISA Laboratories; the INCIDE Foundation; and other organizations committed to advancing Mexico’s pharmaceutical and biotech sectors.
This shared platform will foster meaningful connections between Mexican researchers and companies seeking global collaboration opportunities.
Beyond its role as an exhibitor, UDIBI-IPN is a member of the Mexico Pavilion Executive Committee and has actively contributed to this initiative for the past four years.
Through sustained collaboration with government agencies, industry leaders, and academic institutions, UDIBI-IPN has helped strengthen Mexico’s visibility at the world’s premier biotechnology convention. Its leadership has elevated the Pavilion into a key space for knowledge exchange and the formation of strategic alliances.
Biotech professionals attending BIO 2025 are encouraged to visit booth 1079 to meet with Dr. Sonia Mayra Pérez Tapia, Executive Director of UDIBI-IPN, and Dr. Juan Carlos Almagro, Deputy Director. Meetings may be scheduled through the BIO One-on-One Partnering™ system (https://convention.bio.org/) or via UDIBI-IPN’s Communication Unit at comunicacion@udimeb.com.mx, contacto@udibi.com.mx, or by calling +52 (55) 5729 6000 ext. 62543.
UDIBI’s strength lies in its strategic national and international partnerships, which position it at the forefront of Mexico’s biotechnology sector.
The Unit plays a key role in training IPN students and researchers through collaborative projects, research residencies, and participation in international conferences. Its advanced infrastructure—including facilities for flow cytometry, mass spectrometry, and in vitro/in vivo testing—supports hands-on learning and professional development for students in Biotechnology, Chemical Engineering, Molecular Biology, and related fields.
Through successful technology transfer initiatives, UDIBI has delivered innovative therapies to the Mexican population, benefitting patients and entrepreneurs alike while reinforcing IPN’s role as a national hub for biotherapeutic innovation.
Since its founding, UDIBI-IPN has become a benchmark in the development and production of novel biotherapeutics.
Its cutting-edge facilities support biocompatibility studies, preclinical testing, and the development of therapeutic molecules. Since 2014, UDIBI has contributed to more than 25 biotherapeutic developments and six biosimilars and has evaluated international reference standards including trastuzumab and cetuximab.
Among its major achievements is the transfer of the first innovative Mexican antibody to the national pharmaceutical industry, as well as patents for immunomodulatory agents valid through 2032 in Mexico, the United States, Latin America, and the European Union. These accomplishments further consolidate IPN’s leadership in health-related biotechnology.
Thanks to the expertise and dedication of its academic and technical staff, UDIBI has perfected the design of therapeutic molecules, established robust validation protocols, and successfully transferred advanced technologies to the industrial sector.
This legacy of excellence is reflected in concrete contributions to public health, innovative collaborative research, and the training of graduate students—enhancing IPN’s capacity to lead high-impact scientific and technological initiatives.
INSTITUTO POLITÉCNICO NACIONAL
D.R. Instituto Politécnico Nacional (IPN). Av. Luis Enrique Erro S/N, Unidad Profesional Adolfo López Mateos, Zacatenco, Alcaldía Gustavo A. Madero, C.P. 07738, Ciudad de México. Conmutador: 55 57 29 60 00 / 55 57 29 63 00.
Esta página es una obra intelectual protegida por la Ley Federal del Derecho de Autor, puede ser reproducida con fines no lucrativos, siempre y cuando no se mutile, se cite la fuente completa y su dirección electrónica; su uso para otros fines, requiere autorización previa y por escrito de la Dirección General del Instituto.
